Get the Stockscreener App
1.10
4.35%
-0.05
Cardiol Therapeutics Inc stock is traded at $1.10, with a volume of 586.23K.
It is down -4.35% in the last 24 hours and down -42.11% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.15
Open:
$1.14
24h Volume:
586.23K
Relative Volume:
0.30
Market Cap:
$133.66M
Revenue:
Net Income/Loss:
$-26.33M
P/E Ratio:
-3.8952
EPS:
-0.2824
Net Cash Flow:
$-17.65M
1W Performance:
-10.57%
1M Performance:
-42.11%
6M Performance:
-21.99%
1Y Performance:
+5.77%
1-Day Range:
$1.085
$1.14
1-Week Range:
$1.085
$1.29
52-Week Range:
$0.88
$2.34
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.10 | 133.66M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-26 | Initiated | B. Riley Securities | Buy |
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.
HLS Therapeutics (TSX:HLS) Stock Falls 7.38% Despite Expanded Share Buyback - kalkine.ca
Diluted net income available to common stockholders of Cardiol Therapeutics Inc. Class A – HAN:CT9 - TradingView
Cardiol Therapeutics Inc. (CRDL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
ME Therapeutics Holdings (CN:METX:CNX) Stock Rebounds 14.29%: In Vivo CAR-T and mRNA STING Program Pacing, Micro-Cap Liquidity Dynamics, and Preclinical Biotech Re-Rating Examined - kalkine.ca
Cardiol Therapeutics Inc. (CRDL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares - Kalkine Media
Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan
German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
TSXV:GSD Edges Higher as Devonian Targets NYSE American Listing and Advances Thykamine Development - kalkine.ca
[Form 4] New Fortress Energy Inc. Insider Trading Activity - Stock Titan
Nelnet (NYSE: NNI) director’s stake climbs to 31,953 shares - Stock Titan
Cardiol Therapeutics (Nasdaq: CRDL) opens path to raise cash for heart drug trials - Stock Titan
How Jolt Health (CN:JOLT.X) Could Bring Fresh Energy to Canada's Healthcare Micro-Caps - kalkine.ca
Why Adaptogenics Health (CN:ADPT) Could Ride Growing Interest in Wellness Companies - kalkine.ca
Alta Partners reports 2.1M Envoy Medical (COCH) shares - stocktitan.net
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL) - Seeking Alpha
Cardiol Therapeutics (TSX:CRDL) Slides 12.34% as Volatility Returns and Investors Reassess the Clinical-Stage Risk - kalkine.ca
Cardiol Therapeutics Stock Faces Renewed Pressure as Biotech Risk and Clinical Uncertainty Weigh on Sentiment - kalkine.ca
Cardiol Therapeutics (CRDL) sets terms with new manufacturing and drug ingredient partners - Stock Titan
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com Nigeria
CRDL: Cardiol Therapeutics IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus - TradingView
Cardiol Therapeutics files $150 million shelf prospectus - Investing.com
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com Canada
Cardiol Therapeutics files $150 million shelf prospectus - Investing.com India
New 25‑month shelf lets Cardiol Therapeutics (CRDL) line up future financing - Stock Titan
Cardiol Therapeutics files US$150M base shelf prospectus - TradingView
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission - PR Newswire
Cardiol Therapeutics Inc. (NASDAQ: CRDL) to Host Fireside Chat on September 14 at H.C. Wainwright Investment Conference - Kalkine Media
Cardiol Therapeutics (NASDAQ: CRDL) lines up new shelf to fund drug trials - Stock Titan
Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln - TradingView
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Gains Momentum as Cardiovascular Drug Pipeline Progress Strengthens Investor Optimism - kalkine.ca
US$150M filing does not mean a sale is happening. Cardiol may offer securities later. - Stock Titan
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com UK
Cardiol Therapeutics (TSX:CRDL) Healthcare Stock Latest Update - Kalkine Media
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
ADAG Stock Price, Quote & News - Syfe
Global-E Online (GLBE) officer to sell 12,500 shares in 2026 - Stock Titan
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
WeShop Holdings (WSHP) strategy chief turns 56K options into stock - Stock Titan
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Gains Momentum as Clinical Pipeline Progress and Heart Disease Therapies Drive Investor Optimism - kalkine.ca
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com Canada
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.94%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):